Gentian Diagnostics ASA (OSL:GENT)

Market Cap	684.75M -3.9%
Revenue (ttm)	176.50M +16.1%
Net Income	13.26M -70.7%
EPS	0.86 -70.1%
Shares Out	15.42M
PE Ratio	51.66
Forward PE	16.95
Dividend	0.60 (1.35%)
Ex-Dividend Date	May 6, 2026

Volume	8,626
Average Volume	42,029
Open	44.40
Previous Close	44.40
Day's Range	42.70 - 46.90
52-Week Range	36.10 - 65.80
Beta	0.44
RSI	35.77
Earnings Date	Feb 11, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chro...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 63
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT

Financial Performance

In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.